Now showing items 1-8 of 8

    • Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK-Rearranged Lung Adenocarcinomas 

      Sholl, Lynette Marie; Weremowicz, Stanislawa; Gray, Stacy; Wong, Kwok-Kin; Chirieac, Lucian Radu; Lindeman, Neal I.; Hornick, Jason L. (Elsevier BV, 2013)
      INTRODUCTION ALK gene rearrangements occur in ~5% of lung adenocarcinomas (ACA), leading to ALK overexpression and predicting response to targeted therapy. Fluorescence in situ hybridization (FISH) is the gold standard ...
    • EGFRMutation Is a Better Predictor of Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Carcinoma Than FISH, CISH, and Immunohistochemistry 

      Sholl, Lynette Marie; Xiao, Yun; Joshi, Victoria; Yeap, Beow Yong; Cioffredi, Leigh-Anne; Jackman, David M; Lee, Charles; Janne, Pasi Antero; Lindeman, Neal I. (Oxford University Press (OUP), 2010)
      About 10% of patients with non–small cell lung carcinoma (NSCLC) respond to epidermal growth factor receptor (EGFR)-targeted tyrosine kinase inhibitors (TKIs). More than 75% of “responders” have activating mutations in ...
    • The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine 

      Garofalo, Andrea; Sholl, Lynette; Reardon, Brendan; Taylor-Weiner, Amaro; Amin-Mansour, Ali; Miao, Diana; Liu, David; Oliver, Nelly; MacConaill, Laura; Ducar, Matthew; Rojas-Rudilla, Vanesa; Giannakis, Marios; Ghazani, Arezou; Gray, Stacy; Janne, Pasi; Garber, Judy; Joffe, Steve; Lindeman, Neal; Wagle, Nikhil; Garraway, Levi A.; Van Allen, Eliezer M. (BioMed Central, 2016)
      Background: The diversity of clinical tumor profiling approaches (small panels to whole exomes with matched or unmatched germline analysis) may engender uncertainty about their benefits and liabilities, particularly in ...
    • Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation 

      Van Allen, Eliezer Mendel; Golay, H. G.; Liu, Yan; Koyama, S.; Wong, Kwok-Kin; Taylor-Weiner, Amaro; Giannakis, Marios; Harden, M.; Rojas-Rudilla, V.; Chevalier, A.; Thai, T.; Lydon, C.; Mach, S.; Wong, J. A.; Rabin, A. R.; Helmkamp, J.; Sholl, Lynette Marie; Carter, Scott Lambert; Oxnard, Geoffrey Raymond; Janne, Pasi Antero; Getz, Gad A; Lindeman, Neal I.; Hammerman, Peter Seth; Garraway, Levi Alexander; Hodi, Frank Stephen; Rodig, Scott J.; Dranoff, G; Wong, Kwok-Kin; Barbie, David Allen (American Association for Cancer Research (AACR), 2015)
      PD-1 immune checkpoint blockade occasionally results in durable clinical responses in advanced metastatic cancers. However, mechanism-based predictors of response to this immunotherapy remain incompletely characterized. ...
    • Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study 

      Gray, Stacy W.; Park, Elyse R.; Najita, Julie; Martins, Yolanda; Traeger, Lara; Bair, Elizabeth; Gagne, Joshua; Garber, Judy; Jänne, Pasi A.; Lindeman, Neal; Lowenstein, Carol; Oliver, Nelly; Sholl, Lynette; Van Allen, Eliezer M.; Wagle, Nikhil; Wood, Sam; Garraway, Levi; Joffe, Steven (2016)
      Purpose While targeted sequencing improves outcomes for many cancer patients, how somatic and germline whole-exome sequencing (WES) will integrate into care remains uncertain. Methods: We conducted surveys and interviews, ...
    • Refractory myeloid sarcoma with a FIP1L1-PDGFRA rearrangement detected by clinical high throughput somatic sequencing 

      Mandelker, Diana; Dal Cin, Paola; Jacene, Heather A.; Armand, Philippe; Stone, Richard M.; Lindeman, Neal I. (BioMed Central, 2015)
      Next generation sequencing (NGS) is increasingly being used clinically to characterize the molecular alterations found in patients’ tumors. These testing results have the potential to affect clinical care by guiding ...
    • Training the Future Leaders in Personalized Medicine 

      Mason-Suares, Heather; Sweetser, David A.; Lindeman, Neal I.; Morton, Cynthia C. (MDPI, 2016)
      The era of personalized medicine has arrived, and with it a need for leaders in this discipline. This generation of trainees requires a cadre of new skill sets to lead the implementation of personalized medicine into ...
    • Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine 

      Allen, Eliezer M. Van; Wagle, Nikhil; Stojanov, Petar; Perrin, Danielle L.; Cibulskis, Kristian; Marlow, Sara; Jane-Valbuena, Judit; Friedrich, Dennis C.; Kryukov, Gregory; Carter, Scott L.; McKenna, Aaron; Sivachenko, Andrey; Rosenberg, Mara; Kiezun, Adam; Voet, Douglas; Lawrence, Michael; Lichtenstein, Lee T.; Gentry, Jeff G.; Huang, Franklin W.; Fostel, Jennifer; Farlow, Deborah; Barbie, David; Gandhi, Leena; Lander, Eric S.; Gray, Stacy W.; Joffe, Steven; Janne, Pasi; Garber, Judy; MacConaill, Laura; Lindeman, Neal; Rollins, Barrett; Kantoff, Philip; Fisher, Sheila A.; Gabriel, Stacey; Getz, Gad; Garraway, Levi A. (2013)
      Translating whole exome sequencing (WES) for prospective clinical use may impact the care of cancer patients; however, multiple innovations are necessary for clinical implementation. These include: (1) rapid and robust WES ...